NEW YORK, Sept. 6, 2022 (GLOBE NEWSWIRE) — Juan MonteverdeFounder and managing partner of the collective law firm Monteverde & Associates PC (the “M&A Class Firm”), a nationally rated investment firm top 50 in the 2018-2021 ISS Securities Class Action Services Report and is headquartered at the Empire State Building in New York City Forma Therapeutics Holdingsinc. (FMTX), in connection with the proposed acquisition by Novo Nordisk A/S. Under the terms of the tender offer, FMTX shareholders are expected to receive $20.00 in cash for each share they own. Click here for more information: https://www.monteverdelaw.com/case/forma-therapeutics-holdings-inc. It’s free and there are no costs or obligations to you.
About Monteverde & Associates PC
We are a national securities class action law firm that has recovered millions of dollars and is dedicated to protecting shareholders from corporate wrongdoing. We were listed in the top 50 in the ISS Securities Class Action Services Report 2018-2021. Our attorneys have extensive experience litigating mergers and acquisitions and securities class actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an honor less than 2.5% of attorneys in any given field receive. He was also selected by Martindale-Hubbell as a Top Rated Lawyer 2017-2021. Among our firm’s recent accomplishments is the legislative change in a significant victory that lowered the liability standard under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved that victory by obtaining the dismissal of a carelessly granted warrant by the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S.Ct. 1407 (2019). Also in 2019, we recovered or secured six common cash funds for shareholders in class action lawsuits related to mergers and acquisitions.
If you own common stock in FMTX and wish to receive and protect additional information…
Read full story here https://www.benzinga.com/pressreleases/22/09/g28769668/the-m-a-class-action-firm-announces-the-investigation-of-forma-therapeutics-holdings-inc-fmtx
